Project Details


This program project grant is committed to the development of new
chemotherapeutic strategies. It tightly integrates laboratory
investigators with clinician-scientists resulting in the propagation of
ideas directly from the laboratory into clinical trial. The Section of
Medical Oncology has been realigned to promote this program through Disease
Specific Units. Additional backing comes from the Pharmacology Program
Project Grant (Dr. Alan Sartorelli, P.I.) which explores more speculative
aspects of tumor biology and metabolism to identify leads for developmental
therapeutics. The Comprehensive Cancer Center provides additional support
through its core facilities. Dr. Sartorelli, Director, and Dr. Hait,
Associate Director for Clinical Affairs, are direct links with this
program. Specific projects and their direct applications include: 6-
thioguanine and hypoxanthine to induce differentiation of leukemic cells-
Leukemia Unia (Sartorelli, Todd); the calcium messenger system in squamous
cell differentiation - Head and Neck Unit (Reiss); synergism between BCNU
and thymidine-Neuro-oncology and Lymphoma Units (Prusoff, Cooper); new
agents to overcome multidrug resistance - Breast Unit and others (Hait,
Handschumacher); biochemical aspects to hepatic metastases - GI Unit
(Handschumacher); Genetic transfer of drug-resistance-all units (Cadman).
The Clinical Trials project provides the clinical outlet for the laboratory
programs. The program is supported by four Cores, Administrative,
Biostatistics, Clinical Pharmacology, and Clinical Diagnostics.
Effective start/end date12/31/894/30/95


  • National Cancer Institute


  • Pharmacology (medical)
  • Oncology
  • Cancer Research


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.